PLx Pharma (PLXP) Reports Q1 Revenue of $2.1M, EPS of ($0.66)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
PLx Pharma Inc. Reports First Quarter 2022 Results and Provides Business Update
May 13, 2022 6:50 AM EDTBUILDING A SOLID BASE OF VAZALORE® USERS
Total Net Sales of $2.1 Million in the First Quarter of 2022, an Increase of Approximately 31% from Fourth Quarter of 2021GAAP Net Loss of ($0.39) Per Diluted Share in the First Quarter 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.66) Cash & Cash Equivalent Balance of $52.5 Million as of March 31, 2022Disciplined Spending to Support Strategic GrowthSPARTA, N.J., May 13, 2022 (GLOBE... More
